Table 3.
M1 versus M0 patients: clinical, pathological, and follow-up characteristics.
| M1 | M0 | P value | |
|---|---|---|---|
| Patients | 6 | 124 | |
| Age (±SDa) (range) years | 59.8 ± 16.2 (36–80) | 50.7 ± 14.4 (18–88) | NS* |
| Male/female | 4/2 | 35/89 | NS* |
| Tumour size (±SDa) (range) mm | 33.3 ± 15.6 (20–50) | 28.7 ± 16.7 (5–100) | NS* |
| pT stage | |||
| T1/T2/T3 | 1/1/4 | 22/24/15 | NS* |
| pN stage | |||
| NX/N0/N1 | 6/0/0 | 123/0/1 | NS* |
| MI/WI | 1/5 | 66/58 | NS* |
| HCC | 3 | 60 | NS* |
| Multifocal disease | 0 | 4 | NS* |
| Microcarcinoma | 0 | 7 | NS* |
| Concomitant PTC | 1 | 20 | NS* |
| Follow-up yes/no | 5/1 | 112/12 | NS* |
| Follow-up (±SDa) (range) months | 106.2 ± 49.6 (57–173) | 104.7 ± 39.2 (17–182) | NS* |
SDa: standard deviation; NS*: not significant.